A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial

Erstveröffentlichung
2021
Authors
Grunenberg, Alexander
Kaiser, Lisa M.
Woelfle, Stephanie
Schmelzle, Birgit
Viardot, Andreas
et al.
Wissenschaftlicher Artikel


Published in
BMC Cancer ; 21 (2021), 1. - Art.-Nr. 749. - eISSN 1471-2407
Link to publication
https://dx.doi.org/10.1186/s12885-021-08464-6
Faculties
Medizinische Fakultät
Institutions
UKU. Klinik für Innere Medizin III
UKU. Institut für Experimentelle Tumorforschung
UKU. Institut für Pathologie
Institut für Epidemiologie und Medizinische Biometrie
Subject headings
[Free subject headings]: Marginal zone lymphoma | PI3K inhibitor | Copanlisib | Rituximab | BAY 80-6946 | IDELALISIB | THERAPY | P110-ALPHA | MECHANISM
[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item record